YEBIO was formed in 1999, dominant shareholded by China Animal Health and Epidemiology Center(CAHEC).
Building the foundation to develop business
. 1999, the high and new technology enterprise in Qingdao
. 2002, the inactivated vaccine against avian influenza (AI, H9 subtype) received the new drug certificate
In 2002, YEBIO was restructured into a joint-stock limited liability company, implementing modern enterprise management mechanism.
Taking up the heavy responsibility
. 2004, the state designated AI vaccine manufacturer and exporter
. 2006, the national enterprise research and development center
. In 2007, the genetic engineering subunit vaccine against chicken infectious bursal disease (for the first time in the world) obtained the “National Key New Product” certificate
. In 2008, “3H” products came into market, breaking the monopoly of foreign companies on the Chinese high-end market
. 2010, constructing vaccine supply system for pigs
. 2012, developing genetically-engineered vaccines and readjusting product portfolio
. 2013, National Grade II Prize of Science and Technology Progress and the second prize of State Technological Invention Award
. 2014, the first enterprise that had the national key laboratory of genetically engineered livestock vaccines
. 2015, National and Local Joint Engineering Research Center and National High-tech Enterprise
In 2016, YEBIO made strategic cooperation with CP group to increase capital and shares, expanding into the international market.
. Pursuing the dream of “intelligent manufacturing in China”, with a goal to realize it in YEBIO by 2020
. Registering to go public via IPO within next 2-3 years